Gilteritinib (ASP2215)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Gilteritinib (ASP2215), covering 2022-06-24 to 2025-09-12. Get the full timeline:
Most recent: Clinical Trial Update: A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy [Phase 3]